Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where C. Tate Holbrook is active.

Publication


Featured researches published by C. Tate Holbrook.


Cancer | 1992

Age‐linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the pediatric oncology group

Vijay V. Joshi; Alan Cantor; Geoffrey Altshuler; Ernest W. Larkin; James S. A. Neill; Jonathan J. Shuster; C. Tate Holbrook; F. Ann Hayes; Ruprecht Nitschke; Marilyn H. Duncan; Stephen J. Shochat; James Talbert; E. Ide Smith; Robert P. Castleberry

Histologic sections (minimum of four sections per patient) from 211 patients with neuroblastoma were reviewed. The tumors were resected before therapy, which was standardized according to age and stage. Low mitotic rate (MR) (≤ ten per ten high‐power fields) and calcification emerged as the most significant prognostic features after statistical analysis by stepwise log‐rank tests (P < 0. 0001 and P = 0. 0065, respectively). Histologic Grades 1, 2, and 3 were defined on the basis of the presence of both, any one, or none of these two prognostic features, respectively (Grade 3 had absence of low MR, i.e., these tumors had high MR [> ten per ten high‐power fields]). Statistically significant differences in survival were observed in the grades after adjusting for age and stage (P < 0. 001). The degree of differentiation, although significant by itself, was no longer significant after adjusting for the grades, Age groups (≤ 1 versus > 1 year of age), which also emerged as an independent prognostic feature (P < 0. 001), were linked with the grades to define two risk groups as follows: (1) a low‐risk (LR) group consisting of patients in both age groups with Grade 1 tumors and patients 1 year of age or younger with Grade 2 tumors and (2) a high‐risk (HR) group consisting of patients older than 1 year of age with Grade 2 tumors and patients in both age groups with Grade 3 tumors. The difference in survival between LR (160 cases) and HR groups (51 cases) was statistically significant (P < 0. 001). Concordance between these LR and HR groups and the Shimada classification was observed in 84% of cases. The new histologic grading system has the following advantages: (1) use of familiar terminology and histologic features in the grading system and (2) relative ease of assessment because the degree of differentiation does not need to be determined. The grading system should be tested on a new data set with an appropriate histologic sample of similar size to confirm these results.


Cancer | 1993

Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A pediatric oncology group phase II study

Faith H. Kung; Charles B. Pratt; Roger A. Vega; Norman Jaffe; Douglas Strother; Molly Schwenn; Ruprecht Nitschke; Alan C. Homans; C. Tate Holbrook; Barry Golembe; Mark Bernstein; Jeffrey P. Krischer

Background. The prognosis for children with recurrent or resistant malignant solid tumors remains dismal. More effective rescue therapy is needed for these children.


Cancer | 1992

Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. A clinicopathologic study of 213 cases from the Pediatric Oncology Group.

Vijay V. Joshi; Alan Cantor; Geoffrey Altshuler; Ernest W. Larkin; James S. A. Neill; Jonathan J. Shuster; C. Tate Holbrook; F. Ann Hayes; Robert P. Castleberry

To develop consistency in terminology and pathologic criteria, the authors reviewed the literature and 213 cases of neuroblastic tumors (NT) registered with Pediatric Oncology Group (POG) protocols 8104 and 8441. The patients were given standardized therapy stratified according to POG stage and patient age, and four or more histologic sections of primary tumor resected before therapy were available in each of these 213 cases. All stages were represented. The recommended nomenclature combines conventional terms and criteria with those used by Bove and McAdams and Shimada et al. The main features of the recommended nomenclature are as follows: (1) the terms neuroblastoma (NB) and ganglioneuroblastoma (GNB) are retained instead of stroma‐poor NB and stroma‐rich NB, recommended by Shimada et al.; (2) undifferentiated NB is considered a subtype separate from poorly differentiated NB; and (3) the term GNB is used only when there is a predominant ganglioneuromatous component admixed with the minor neuroblastomatous component. With the use of these criteria and terms, the Shimada classification was determined in the 213 cases. The results showed that, even after stratification for age, POG stage, and primary site, there is a statistically significant difference in survival rate between favorable histologic and unfavorable histologic prognostic subgroups. The authors recommend that definitive prognostic categorization of an NT according to Shimada classification should be done only when adequate histologic material is available from a primary tumor resected before any other therapy. Categorization done on histologic material from small biopsy specimens, previously treated primary tumors, or meta‐static sites should be considered tentative.


Cancer | 1993

Correlation between Morphologic and Other Prognostic Markers of Neuroblastoma A Study of Histologic Grade, DNA Index, N-myc Gene Copy Number, and Lactic Dehydrogenase in Patients in the Pediatric Oncology Group

Vijay V. Joshi; Ernest W. Larkin; C. Tate Holbrook; Jan F. Silverman; H. Thomas Norris; Alan B. Cantor; Jonathan J. Shuster; Garrett M. Brodeur; A. Thomas Look; F. Ann Hayes; Geoffrey Altshuler; E. Ide Smith; Robert P. Castleberry

Background. Histologic grades (HG), N‐myc (NM) gene copy number, DNA index (DI), and serum lactic dehydrogenase (LDH) have been shown to be related to prognosis in neuroblastoma. The relationship between HG and nonmorphologic prognostic markers has not been investigated previously.


Human Pathology | 1993

Systematization of primary histopathologic and fine-needle aspiration cytologic features and description of unusual histopathologic features of neuroblastic tumors: A report from the pediatric oncology group

Vijay V. Joshi; Jan F. Silverman; Geoffrey Altshuler; Alan Cantor; Ernest W. Larkin; James S. A. Neill; H. Thomas Norris; Jonathan J. Shuster; C. Tate Holbrook; F. Ann Hayes; E. Ide Smith; Robert P. Castleberry

On the basis of a detailed review of the primary histopathologic features of 239 cases and the fine-needle aspiration cytologic features of seven cases, a systematized schema of differentiation, progressive maturation and organization, and biologic behavior in neuroblastic tumors (NTs) is presented. The differentiation is of the gangliocytic and schwannian lineages. Maturation occurs in differentiating neuroblasts, leading to the formation of various stages of ganglion cells and Schwann cells. Organization is characterized by nesting pattern, rosette formation, parallel arrangement of neuropil, and alignment of Schwann cells along the neurites. According to this schema the NTs can be arranged in the following order: undifferentiated, poorly differentiated, and differentiating neuroblastoma; nodular, intermixed, and borderline ganglioneuroblastoma; and ganglioneuroma. Formulation of such a schema is helpful in gaining a better understanding of the complex pathologic features and in defining the criteria for various types of NTs. Therefore, the schema also would be helpful in achieving uniformity and reproducibility of the diagnosis of various types of NTs. Previously unreported features related to shape, size, nucleus, and cytoplasm of neuroblasts; secondary changes and patterns; changes in the fibrovascular septa; and other morphologic aspects of NTs and features (such as large tumor cells, karyorrhectic cells in fine-needle aspiration biopsy, tumor giant cells, anaplasia, and nesting pattern of tumor cells that have not been sufficiently emphasized) also are described. The importance of these previously unreported and insufficiently emphasized features relates to the histologic and cytologic diagnosis of NTs. For example, some of the features, such as starry sky appearance and spindle-shaped neuroblasts, may be misleading if seen in a small biopsy specimen. Others, such as tumor giant cells resembling ganglion cells and nesting pattern, will provide clues to the correct diagnosis. Some of the features, such as sclerosing pattern, hyalinization, and dense lymphoplasmacytic infiltration, may be related to the phenomenon of regression exhibited by neuroblastomas.


Journal of Child Neurology | 1986

Chronic Renal Failure Presenting as Proximal Muscle Weakness in a Child

Jeanne S. Berretta; C. Tate Holbrook; Jerome S. Haller

A 13-year old boy presented with a three-year history of slowly progressive proximal muscle weakness, particularly involving the lower extremities. Chronic renal failure was uncovered in the course of his evaluation. Urologic investigation showed small and poorly functioning kidneys with a BUN of 118 mg/dL and a creatinine of 10.7 mg/dL. There were no anomalies of the proximal or distal collecting systems or history suggestive of recurrent urinary tract infection. The neurologic examination revealed proximal muscle weakness primarily of the lower extremities and especially of the proximal musculature of the pelvic girdle. Nerve conduction studies were normal. The electromyogram (EMG) showed high-voltage polyphasic potentials consistent with neurogenic muscle disease. A biopsy of the right quadriceps muscle demonstrated type II muscle fiber atrophy with histochemical staining. The patients clinical findings, EMG studies, and muscle biopsy were not specific for either neurogenic or myopathic disease. Following a period of home peritoneal dialysis and renal transplantation, there was significant clinical improvement of the muscle weakness. (J Child Neurol 1986;1:50-52)


Diagnostic Cytopathology | 1991

Fine-needle aspiration cytology of Langerhans' cell histiocytosis (Eosinophilic granuloma) of bone in children

Tarik M. Elsheikh; Jan F. Silverman; Paul E. Wakely; C. Tate Holbrook; Vijay V. Joshi


JAMA Pediatrics | 1980

Vasoactive Intestinal Peptide Secreting Tumors of Childhood

Saul J. Kaplan; C. Tate Holbrook; Huey G. McDaniel; William L. Buntain; William M. Crist


The Journal of Pediatrics | 1978

Acute leukemia and hypopyon

C. Tate Holbrook; Frederick J. Elsas; William M. Crist; Robert P. Castleberry


Diagnostic Cytopathology | 1993

Cytomorphology of familial hemophagocytic syndrome.

Jan F. Silverman; Harsharan K. Singh; Vijay V. Joshi; C. Tate Holbrook; Allen R. Chauvenet; Lawrence S. Harris; Kim R. Geisinger

Collaboration


Dive into the C. Tate Holbrook's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert P. Castleberry

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

F. Ann Hayes

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge